Publication:
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy

Simple item page
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorsDulgar O., Oven B. B., Atci M. M., Arikan R., Ay S., Ayhan M., Selvi O., Ozyukseler D. T., Bayram E., ÖZCAN E., et al.
dc.date.accessioned2023-07-10T13:06:20Z
dc.date.available2023-07-10T13:06:20Z
dc.date.issued2022-01-01
dc.description.abstractBackground Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear. Materials and Methods We analyzed data of 160 consecutive patients with residual TNBC from eight cancer-center. Pathologic response was defined into two groups as having good-pathologic-response (MillerPayneGrading (MPG) IV-III) or poor-pathologic-response (MPG I-II). The characteristics of patients were compared regarding adjuvant capecitabine usage. Results Univariate-analysis revealed that age, histology, clinical-stage, tumor-size, lymph-nodes number, menopausal status, and pathological-stage were significantly different between two groups. In multivariate-analysis, menopausal status (p = 0.043) and residual tumor-size (p < 0.001) were found to be independent prognostic factors for pathological response. The hazard-ratio for disease recurrence and death in the poor-response group with adjuvant capecitabine was 2.94 (95% confidence-interval (CI), 1.21 to 7.10; p = 0.016) and 4.080 (95% CI, 1.22 to 13.64; p = 0.022), respectively. DFS (p = 0.58) and OS (p = 0.89) improvements with adjuvant capecitabine were not demonstrated in good-response groups. Conclusion This multicenter-study suggested that only the poor-response group to NAC achieved benefit from adjuvant capecitabine. Postmenopausal status and residual tumor-size were related to poor prognosis.
dc.identifier.citationDulgar O., Oven B. B., Atci M. M., Arikan R., Ay S., Ayhan M., Selvi O., Ozyukseler D. T., Bayram E., ÖZCAN E., et al., "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?", EXPERT REVIEW OF ANTICANCER THERAPY, cilt.22, sa.7, ss.773-780, 2022
dc.identifier.doi10.1080/14737140.2022.2076670
dc.identifier.endpage780
dc.identifier.issn1473-7140
dc.identifier.issue7
dc.identifier.startpage773
dc.identifier.urihttps://hdl.handle.net/11424/291069
dc.identifier.volume22
dc.language.isoeng
dc.relation.ispartofEXPERT REVIEW OF ANTICANCER THERAPY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectTriple negative breast cancer
dc.subjectneoadjuvant chemotherapy response
dc.subjectpathological response
dc.subjectresidual tumor size
dc.subjectadjuvant capecitabine
dc.subjectCYCLOPHOSPHAMIDE
dc.subjectEPIRUBICIN
dc.subjectDOCETAXEL
dc.titleIs the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy
dc.typearticle
dspace.entity.typePublication
local.avesis.id2669f7c1-a2aa-4d0b-b3d2-f4b1d0689a5c
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication.latestForDiscovery22952072-1852-47c4-b1ff-669ac16d2ad6

Files

Collections

Research Outputs